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The present study evaluated the effects of doxorubicin (DOX) and dera-
coxib (DER), as single agents and in combination treatments, on antioxidant pa-
rameters in the canine mammary carcinoma cell line CMT-U27. The cells were 
exposed to DOX and DER for 24, 48 and 72 h. The viability and malondialdehyde 
(MDA), nitric oxide (NO), catalase (CAT), superoxide dismutase (SOD), glu-
tathione peroxidase (GSHPx) and total glutathione (GSH) activities of CMT-U27 
cells were determined. The half inhibition concentration (IC50) of DOX was found 
to be ~0.9 μM in the 72-h period. IC50 and 1/10 IC50 concentrations of DOX were 
combined with all concentrations of DER (50–1000 µM) in the combination ex-
periments. The results showed increased oxidative status associated with signifi-
cant decreases of CAT and GSH levels in CMT-U27 cells exposed to 10-µM and 
higher concentrations of DOX compared to control cells. In contrast, there were 
no significant changes in the groups tested with any of the concentrations of DER 
(50–1000 µM). In combination treatments, DER attenuated DOX-induced oxida-
tive damage by modulating the enzymatic and non-enzymatic components in 
CMT-U27 cells. We suggest that the combination of DOX and DER can be bene-
ficial in the treatment of cancer cells by increasing cellular responses to oxidative 
stress. In conclusion, the use of COX inhibitor in conjunction with a chemothera-
peutic agent may provide a basis for new concepts of cancer treatment through 
systematic modulation of the antioxidant defence systems in mammary cancers of 
animals. 
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Canine mammary tumours are the most common type of tumours, com-
prising about 50% of all neoplasms in female dogs (Karayannopoulou et al., 
2001). The modalities used in the treatment of canine mammary cancer include 
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surgery, radiotherapy or chemotherapy (Sorenmo, 2003). Chemotherapeutic re-
gimes have been attempted in dogs with gross metastatic disease. Among the 
chemotherapeutic agents, anthracyclines such as doxorubicin (DOX) have been 
frequently used for their potent efficiency in controlling the distant spread of the 
disease (Pagnini et al., 2000). However, DOX continues to pose serious concern 
for the hazard of undesirable tissue consequences, such as generation of reactive 
oxygen species (ROS) resulting in oxidative stress and cellular changes. Over-
production of ROS can cause oxidative damage to biomolecules (lipids, proteins, 
DNA) and induce mitochondrial dysfunction and cell death, eventually leading to 
many chronic diseases including cardiovascular diseases, neural disorders, 
atherosclerosis, chronic inflammation, diabetes, cancer and other degenerative 
diseases (Uttara et al., 2009). 
A disturbance of the balance between the formation of active oxygen me-
tabolites and the rate at which they are scavenged by enzymatic and nonenzy-
matic antioxidants is referred to as oxidative stress (Papas, 1996). The extent of 
ROS-induced oxidative damage can be exacerbated by a decreased efficiency of 
antioxidant defence mechanisms. Endogenous defences against ROS include an-
tioxidant enzymes such as catalase (CAT), superoxide dismutase (SOD) and glu-
tathione peroxidase (GSHPx), and the markers of oxidative and nitrosative stress 
are malondialdehyde (MDA) and nitric oxide (NO) (Ray et al., 2000). 
Oxidative stress is also a characteristic feature of inflammation, with epi-
demiological studies suggesting its positive association with cancer incidence in 
humans and animals with various types of cancer. In recent years, in vitro studies 
and clinical trials have shown that nonsteroidal anti-inflammatory drugs 
(NSAIDs) can modulate oxidative stress and contribute to decreasing the risk of 
several cancers (Antunes et al., 2007). Cyclooxygenase (COX) enzyme inhibi-
tion, which constitutes the primary mechanism of the anti-inflammatory action of 
NSAIDs, is believed to account for the suppression of cancer cell proliferation 
and tumor development. ROS are produced during the inflammatory response as 
a consequence of COX activity. However, it has been suggested that the anti-
inflammatory activity of NSAIDs may be also partly due to their ability to scav-
enge ROS (Fernandes et al., 2004). Since anti-inflammatory drugs can reduce 
oxygen radical species, such as superoxide anion, hydroxyl radical and hydrogen 
peroxide produced by inflammatory cells, they have been suggested to be effec-
tive antioxidant and protective agents (Antunes et al., 2007). 
Recently, numerous experimental, epidemiological and clinical studies 
have demonstrated that NSAIDs, particularly the highly selective COX-2 inhibi-
tors, are promising cancer chemopreventive agents (Rao and Reddy, 2004). De-
racoxib (4-[5-(3-difluoro–4-methoxyphenyl)-(difluoromethyl)-1H pyrazole-1-yl] 
benzenesulphonamide) (DER) is a selective COX-2 inhibitor licensed for the 
treatment of pain and inflammation associated with osteoarthritis and orthopae-
dic surgery in canines (Cox et al., 2005). DER has been reported to possess po-
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tent antioxidant activity besides its anti-inflammatory effect (Yanez et al., 2008). 
On the basis of the concerns, we investigated the efficiency of the administration 
of DER with regard to its antioxidant ability in comparison to DOX as single 
agents and in combination treatments, on proliferation in conjunction with the 
levels of antioxidant parameters in CMT-U27 canine mammary carcinoma cell 
line. 
 
Materials and methods 
Chemicals 
Except otherwise indicated, all reagents were purchased from Sigma 
Chemical Co. (St. Louis, MO, USA). MTT Cell Proliferation kit and Superoxide 
dismutase assay kit were purchased from Roche Applied Science (Mannheim, 
Germany) and Randox Laboratories Ltd. (UK), respectively. DER was a generous 
gift from Novartis Pharmaceuticals Inc. (Basle, Switzerland). 
Cell culture and treatment 
The canine mammary carcinoma cell line CMT-U27 was kindly supplied 
by Prof. Eva Héllmen (Uppsala University, Sweden). Cells were cultured in 
DMEM-F12 supplemented with 10% fetal bovine serum, 1% L-glutamine and 1% 
antibiotic and antimycotic solution in a humidified atmosphere at 37 °C under 
5% CO2 and 95% air. Culture media were changed every 2–3 days to maintain 
the exponential growth of the cells. DOX and DER were dissolved in DMEM-
F12 and sterile DMSO, respectively, and further serial dilutions for both drugs 
were made with DMEM-F12. All of the stock solutions were kept at –20 °C. 
Cell viability assay 
The cells were seeded at 1 × 104 per well in a final volume of 100 μL in 
96-well flat-bottomed tissue culture plates and incubated in a humidified atmos-
phere at 37 °C under 5% CO2 and 95% air to allow cell adhesion. After incubation, 
the medium was removed and cells were treated with various concentrations of 
DOX (0.1, 1, 10, 50 and 100 μM) and DER (50, 100, 250, 500 and 1000 μM) for 
24, 48 and 72 h. The concentrations for DOX were chosen on the basis of previ-
ous reports about the effects of this drug on the in vitro viability of canine mam-
mary tumour cells (Pagnini et al., 2000). The tested DER levels were selected 
according to the values reported in an earlier study (Royals et al., 2005) to cause 
inhibition of proliferation of a canine osteosarcoma cell line. Cell viability, based 
on mitochondrial dehydrogenase activity, was determined using the colorimetric 
assay MTT (3-(4,5)-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) Cell 
Proliferation Kit in accordance with the instruction manual. The optical density 
of each well at 550 nm against a reference wavelength of 650 nm was measured 
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using a microplate reader (ELx800, Biotek Instruments, USA). The cell viability 
was calculated as follows: Viability (%) = (Absorbance of the treated wells)/ 
(Absorbance of the control wells) × 100. Each concentration was tested in three 
different experiments and run in triplicate. The dose-response curves were plot-
ted for each drug and the concentration of drug required for 50% inhibition of 
cell viability (IC50) was determined graphically. In drug combination experi-
ments, the IC50 and 1/10 IC50 concentrations of DOX were used in combination 
with all concentrations of DER for 72 h. 
Determination of oxidative stress markers  
and enzymatic and non-enzymatic antioxidants 
Enzymatic (CAT, SOD, GSHPx) and non-enzymatic antioxidants (GSH) 
were determined in cell lysates prepared according to the method described by 
Jung et al. (1997). Briefly, cell pellets were suspended in 0.1% Triton X-100 so-
lution in 10 mM phosphate buffer (pH 7.2) and sonicated. After centrifugation 
(13,000 × g; 10 min), the supernatants of cell lysates were collected and stored 
until analysis of MDA, CAT, SOD, GSHPx and GSH at −80 °C. The protein 
content of the cell lysates was measured using the Total Protein Kit for lipid per-
oxidation, catalase and superoxide dismutase assays (Sigma, St. Louis, MO). 
Each experiment was carried out in triplicate. 
Lipid peroxidation assay  
Lipid peroxidation products were quantified by measuring thiobarbituric 
acid reactive substances and expressed as MDA (Draper and Hadley, 1990). The 
cells were seeded at 2.5 × 105 per well in a final volume of 1000 μL in 24-well 
flat-bottomed tissue culture plates and incubated in a humidified atmosphere at 
37 °C under 5% CO2 and 95% air to allow cell adhesion. Subsequently, the me-
dium was removed and fresh medium containing various concentrations of drugs 
as mentioned in the MTT test were added and incubated at 37 °C in a 5% CO2 
atmosphere incubator for 72 h. After the incubation period, the experiment was 
performed according to the method described by Kim et al. (2007). The results 
were expressed as MDA formation per mg protein. 
Nitric oxide (NO) assay 
The cells were seeded at 1 × 105 per well in a final volume of 1000 μL in 
24-well flat-bottomed tissue culture plates and incubated as mentioned under the 
lipid peroxidation assay. At the end of the incubation period the supernatants 
were collected. The concentration of nitrites (NO2) in supernatants of cells was 
taken as a measure of NO production and determined via the Griess reaction. Op-
tical density was determined at 530 nm with a microplate reader and NO2 levels 
were measured by comparison to the sodium nitrite (NaNO2) standard curve 
(Chen et al., 2008). 
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Catalase (CAT) assay 
CAT activity was determined by the spectrophotometric method by meas-
uring the decomposition of H2O2 at 240 nm using an extinction coefficient of 
43.6 M–1 cm–1 and an initial H2O2 concentration of 54 mM. One unit of CAT ac-
tivity is defined as the amount of enzyme catalysing the breakdown of 1 μmol of 
H2O2 per min at 25 °C (Beer and Sizer, 1952). Each unit was expressed as activ-
ity per mg protein. 
Superoxide dismutase (SOD) assay 
The SOD activity assay was based on the ability of the enzyme to convert 
superoxide radicals, produced by X/XO, to hydrogen peroxide, inhibiting indica-
tor oxidation and colour formation. The possible influence of drugs on the SOD 
activity were determined with a RANSOD test kit (Randox Laboratories Ltd., 
UK) as described by Rengel et al. (2005). Each unit was expressed as activity per 
mg protein. 
Glutathione peroxidase (GSHPx) assay 
GSHPx activity was determined with a spectrophotometer by measuring 
the rate of NADPH oxidation at 340 nm (Koh, 2001). The decrease in A340 was 
recorded for 6 min at 1-min intervals. Enzyme activity was calculated by using 
the millimolar extinction coefficient of NADPH (6.22). One milliunit of GSHPx 
oxidises 1 nmol of GSH per min. 
Glutathione (GSH) assay 
Samples were examined for the level of GSH by Tietze’s method de-
scribed by Durgo et al. (2007). The absorbance was determined at 412 nm every 
15 sec for 2 min. The concentration of total GSH was calculated from the stan-
dard curve. 
Statistical analysis 
Data were analysed by one-way analysis of variance (ANOVA) followed by 
Student’s t-test using the ‘Instat’ statistical computer programme. Results were ex-
pressed as the mean ± SE. Differences were considered statistically significant at 
a P value of 0.05 or less. 
 
Results 
Cell viability assay 
DOX and DER displayed dose- and time-dependent antiproliferative ef-
fects in CMT-U27 cells (data not shown). After 72-h incubation, a significant re-
duction in cell numbers was seen in the presence of all concentrations of DOX 
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(P < 0.001) and 250 µM, 500 µM (P < 0.05) and 1000 µM of DER (P < 0.01) 
(Fig. 1). The IC50 value was calculated for DOX and DER at concentrations of 
0.876 μM and 974.481 μM, respectively, after 72-h incubation. Accordingly, the 
IC50 and 1/10 IC50 values of DOX were used in the subsequent studies on oxida-
tive stress. The combinations of IC50 and 1/10 IC50 values of DOX with the high-
est dose of DER resulted in significant reductions of cell viability (P < 0.05, P < 
0.01), respectively (Fig. 2). 
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Fig. 1. CMT-U27 cell viability after 72-h exposure to DOX and DER. Values are mean ± SE from 
three independent experiments. Significant differences indicated as ***P < 0.001 DOX vs. control 
group, *P < 0.05 and **P < 0.01 DER vs. control group 
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Fig. 2. CMT-U27 cell viability after 72-h exposure to DOX and DER combination. Values are 
mean ± SE from three independent experiments. Significant differences indicated as *P < 0.05 
DOX combinations vs. DOX (0.9 µM), **P < 0.01 DOX combinations vs. DOX (0.09 µM) 
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Table 1 
MDA, NO2, CAT, SOD, GSHPx and GSH levels of CMT-U27 cells after 72-h exposure to DOX and DER 
Parametersa 
Concentrations  
of drugsb MDA,  
nmol/mg protein 
NO2,  
µM 
CAT,  
U/mg protein 
SOD,  
U/mg protein 
GSHPx,  
nmol/mL 
GSH,  
µM 
Control 5.63 ± 0.24 3.45 ± 0.82 1.76 ± 0.05 0.30 ± 0.02 463.52 ± 17.39 1.48 ± 0.04 
DOX 0.1 µM 8.68 ± 1.04 3.71 ± 1.01 1.23 ± 0.70 0.29 ± 0.01 371.89 ± 20.59 1.41 ± 0.03 
DOX 1 µM 9.60 ± 0.23 4.64 ± 0.95 1.12 ± 0.58 0.26 ± 0.01 355.44 ± 17.13 1.16 ± 0.04 
DOX 10 µM 9.46 ± 0.39 4.17 ± 0.18 0.93 ± 0.49* 0.23 ± 0.02 330.52 ± 10.85 0.95 ± 0.04* 
DOX 50 µM 10.15 ± 1.95 6.25 ± 0.23 0.91 ± 0.04* 0.20 ± 0.01 327.64 ± 9.10 0.93 ± 0.02* 
DOX 100 µM 21.34 ± 0.48* 14.89 ± 0.17* 0.88 ± 0.07* 0.12 ± 0.01* 278.51 ± 14.34* 0.88 ± 0.04* 
DER 50 µM 3.76 ± 0.80 4.18 ± 0.14 1.84 ± 0.05 0.27 ± 0.01 407.38 ± 11.58 1.19 ± 0.06 
DER 100 µM 3.70 ± 0.29 4.05 ± 0.18 2.07 ± 0.07 0.28 ± 0.01 444.33 ± 9.88 1.31 ± 0.05 
DER 250 µM 4.49 ± 0.63 2.02 ± 0.20 2.57 ± 0.08 0.30 ± 0.01 472.41 ± 13.86 1.39 ± 0.04 
DER 500 µM 7.46 ± 0.07 1.87 ± 0.19 2.65 ± 0.08 0.34 ± 0.02 592.44 ± 15.27 1.84 ± 0.04 
DER 1000 µM 7.21 ± 0.70 2.63 ± 0.41 2.73 ± 0.06 0.43 ± 0.02 625.42 ± 12.38 1.95 ± 0.06 
aMDA, malondialdehyde; NO2, nitrite; CAT, catalase; SOD, superoxide dismutase; GSHPx, glutathione peroxidase; GSH, glutathione; bDOX, 
Doxorubicin; DER, Deracoxib. Each value represents the mean ± SE of three experiments; *P < 0.05 compared to the control group 
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Table 2 
MDA, NO2, CAT, SOD, GSHPx and GSH levels of CMT-U27 cells after 72-h exposure to DOX and DER combination 
Parametersa 
Concentrations  
of drugsb (µM) MDA,  
nmol/mg protein 
NO2,  
µM 
CAT,  
U/mg protein 
SOD,  
U/mg protein 
GSHPx,  
nmol/mL 
GSH,  
µM 
Control 5.63 ± 0.24 3.45 ± 0.82 1.76 ± 0.05 0.30 ± 0.02 463.52 ± 17.39 1.48 ± 0.04 
DOX 0.9  8.85 ± 0.39 4.53 ± 0.35 1.34 ± 0.03 0.27 ± 0.02 364.34 ± 10.07 1.22 ± 0.03 
DOX 0.9 + DER 50  5.43 ± 0.33 4.00 ± 0.06 1.23 ± 0.05 0.26 ± 0.01 330.46 ± 7.38 1.11 ± 0.12 
DOX 0.9 + DER 100  7.47 ± 0.99 2.77 ± 0.67 1.71 ± 0.06 0.28 ± 0.03 441.86 ± 8.94 1.33 ± 0.03 
DOX 0.9 + DER 250  7.72 ± 0.16 1.04 ± 0.14 1.80 ± 0.05 0.33 ± 0.02 460.17 ± 15.61 1.26 ± 0.02 
DOX 0.9 + DER 500  8.01 ± 0.36 1.76 ± 0.20 1.98 ± 0.07 0.34 ± 0.04 540.67 ± 18.07 1.68 ± 0.04 
DOX 0.9 + DER 1000  8.67 ± 0.44 1.01 ± 0.23 2.53 ± 0.08* 0.36 ± 0.04 606.18 ± 12.14* 2.07 ± 0.01* 
DOX 0.09 7.47 ± 0.13 3.63 ± 0.34 1.41 ± 0.02 0.29 ± 0.01 376.91 ± 9.39 1.39 ± 0.04 
DOX 0.09 + DER 50  6.61 ± 0.71 3.09 ± 0.124 1.66 ± 0.05 0.30 ± 0.01 341.95 ± 14.27 1.20 ± 0.01 
DOX 0.09 + DER 100  6.66 ± 0.37 2.37 ± 0.29 1.77 ± 0.08 0.34 ± 0.03 387.09 ± 11.76 1.50 ± 0.02 
DOX 0.09 + DER 250  5.99 ± 0.58 2.06 ± 0.03 1.91 ± 0.07 0.34 ± 0.04 538.39 ± 16.67 1.52 ± 0.03  
DOX 0.09 + DER 500 6.44 ± 0.36 1.99 ± 0.08 2.26 ± 0.06 0.37 ± 0.04 799.76 ± 21.84** 2.03 ± 0.08 
DOX 0.09 + DER 1000  6.62 ± 0.29  2.28 ± 0.32 2.62 ± 0.05* 0.41 ± 0.06 781.93 ± 26.47** 2.15 ± 0.06* 
aMDA, malondialdehyde; NO2, nitrite; CAT, catalase; SOD, superoxide dismutase; GSHPx, glutathione peroxidase; GSH, glutathione; bDOX, 
Doxorubicin; DER, Deracoxib. Each value represents the mean ± SE of three experiments; *P < 0.05 compared to DOX (0.9 µM and 0.09 µM); 
**P < 0.01 compared to DOX (0.9 µM and 0.09 µM) 
380 ÜSTÜN ALKAN et al. 
Acta Veterinaria Hungarica 62, 2014 
Determination of oxidative stress markers  
and enzymatic and non-enzymatic antioxidants 
The effects of DOX and DER on MDA, NO2, CAT, SOD, GSHPx and 
GSH levels in CMT-U27 cells are shown in Table 1. The effects of the combina-
tion of DOX and DER on MDA, NO2, CAT, SOD, GSHPx and GSH levels in 
CMT-U27 cells are shown in Table 2. 
Lipid peroxidation assay 
The highest dose of DOX (100 µM) markedly increased MDA levels (P < 
0.05), whereas DER had no significant effect on lipid peroxidation. However, 
DER in combination with DOX suppressed lipid peroxidation but this suppres-
sion was not statistically significant (P > 0.05). 
Nitric oxide assay 
As the data show, DOX increased the NO2 release when compared with the 
control. A significant increase (P < 0.05) was seen at the highest dose (100 µM), 
whereas none of the doses of DER had significant effects on NO2 levels when 
compared with the control. A small and statistically insignificant (P > 0.05) ef-
fect on NO2 levels was observed for DOX combinations with all doses of DER 
when compared with DOX (0.9 and 0.09 µM). 
Catalase (CAT) assay 
CAT levels were decreased in a dose-dependent manner and a significant 
reduction (P < 0.05) was seen at 10 µM and higher concentrations of DOX. How-
ever, DER had no significant effect on CAT levels. In contrast, significant rises 
(P < 0.05) in CAT levels were detected after treatment with 0.9 µM and 0.09 µM 
concentrations of DOX combined with the highest dose (1000 µM) of DER. 
Superoxide dismutase (SOD) assay 
The SOD levels were significantly decreased (P < 0.05) in the presence of 
DOX (100 µM), whereas the relatively small increases in SOD levels seen after 
treatment with DER (250–1000 µM) in comparison with the control were not sta-
tistically significant (P > 0.05). The combination of DOX with DER had no sig-
nificant effect on SOD levels when compared with DOX (0.9 and 0.09 µM). 
Glutathione peroxidase (GSHPx) assay 
DOX (100 µM) significantly decreased GSHPx activity in comparison 
with the control group (P < 0.05), while the small increases induced in the activ-
ity of GSHPx by 250 µM and higher concentrations of DER did not carry statis-
tical significance. Combined treatment with DOX and DER (0.9 µM DOX + 
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1000 µM DER, 0.09 µM DOX + 500 µM DER and 0.09 µM DOX + 1000 µM DER) 
significantly increased the GSHPx level compared to DOX alone at 0.9 and 0.09 µM 
(P < 0.05, P < 0.01). 
Glutathione (GSH) assay 
DOX decreased the GSH levels significantly at 10 µM and higher doses 
(P < 0.05) and there was a tendency for an increase in GSH concentrations at 500 
and 1000 µM concentrations of DER. However, DOX treatment combined with 
1000 µM of DER caused a more than 1.55- to 1.70-fold increase in GSH levels 
in CMT-U27 cells when compared with DOX used alone at 0.9 and 0.09 µM. 
 
 
Discussion 
Cellular mechanisms and external factors involved in the production of 
oxidative stress include the inflammatory response, free radical leak from mito-
chondria, auto-oxidation of catecholamines, xanthine oxidase activation and pro-
oxidant activities of toxins. Aerobic cells are endowed with extensive antioxidant 
defence mechanisms including low molecular weight scavengers and enzymatic 
systems such as SOD, CAT, GSHPx and GSH, which counteract the damaging 
effects of ROS (Russo et al., 2005). 
DOX is a potent chemotherapeutic agent, used for the treatment of canine 
mammary cancer (Sorenmo, 2003). Application of this drug can cause serious 
side effects in various tissues including kidney and brain (nephrotoxicity and 
neurotoxicity), apart from the known serious cardiotoxic side effects which are 
caused by the free radical formation activity of DOX (Joshi et al., 2005). These 
side effects limit the successful use of this drug in the treatment of cancer (Ko-
tamraju et al., 2000). The cellular and biochemical changes involved in the 
DOX-induced injury of membrane lipids have been demonstrated (Shiromwar 
and Chidrawar, 2011). Modulations of the oxidant status by systemic alteration 
of the enzymatic antioxidant systems and of the nonenzymatic components as 
well as by inducing an increased release of radicals have recently been under dis-
cussion as concepts of cancer treatment. We consider the data obtained in the 
present study as a basis for further investigations in this field. 
Lipid peroxidation initiated by ROS is a complex process that occurs in 
multiple stages, and measurements of MDA levels as well as GSH content and 
antioxidant enzyme activities have been used as markers for oxidative stress in 
cultures in vitro (Alía et al., 2006). The most important mechanism for free radical 
scavenging and inhibition of electrophilic xenobiotics attack on cellular macro-
molecules involves tripeptide GSH (Durgo et al., 2007). GSH is one of the most 
abundant thiol-containing molecules in animal cells, which plays an important 
role in the protection of tissues from the toxic effects of xenobiotics and endoge-
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nous electrophiles. Reactive intermediates can react with GSH either by a direct 
chemical reaction or by a glutathione-S-transferase mediated reaction preventing 
possible cell death (Forman et al., 2009). In the present study, there was a decrease 
in GSH concentration in DOX-treated cells compared with the control group. 
This decrease may be caused by GSH reacting with increased free radicals or 
lipid peroxides. However, the combination of 1000 µM of DER with the IC50 and 
1/10 IC50 values of DOX significantly increased the GSH levels in CMT-U27 cells 
as compared with the IC50 and 1/10 IC50 values of DOX alone. This indicates that 
cells treated with DER can tolerate exposure to higher concentrations of DOX as 
well as antineoplastic drugs that cause oxidative damage and oxidative stress. 
CAT is a primary antioxidant defence that converts H2O2 to O2 and water, 
and SOD is thought to provide a primary line of defence by catalysing the dismu-
tation of the one-electron reduction product of oxygen O2 to H2O2 and O2, and 
SOD has a central role in the protection of cancer cells against intrinsic oxidative 
stress (Oberley and Buettner, 1979; Valko et al., 2006). Decreased CAT activity 
in tumour cells leads to the accumulation of H2O2, which causes DNA damage 
and/or cell death (Er et al., 2004). Also, H2O2 is believed to be involved in the 
initiation and promotion of carcinogenesis (Pryor, 1986). The significant de-
crease in CAT levels might be a result of excess production of H2O2 and conse-
quently free radicals. CAT might act as a compensatory mechanism to overcome 
the excess of H2O2. The increase in CAT levels seen after combined treatment 
may be due to the antioxidant activity of DER. The lowered values of CAT, SOD 
and GSH found in this study strongly prove the oxidative damage caused by 
DOX. In addition, it was observed that DER was capable of restoring CAT, SOD 
and GSH that had been reduced by DOX. However, significant increases in CAT 
and GSH levels were found only at the highest concentration of DER. The reduc-
tion of oxidative stress by DER can be explained by the potential antioxidant ca-
pacity of DER. This argument is supported by the finding that DER had a stead-
ily high antioxidant activity (~0.4 mM) when measured by the ABTS method 
(Yanez et al., 2008). The alterations caused in antioxidant enzyme activities by 
DER may be due to direct scavenging of the peroxyl radical or by donating re-
ducing equivalents to the peroxyl radical (Ajith et al., 2005). 
In the present study, DOX significantly reduced cell viability in a time-
dependent manner. DER had only minimal effect on DOX-induced cytotoxicity 
when combined with the IC50 and 1/10 IC50 values of DOX. Only the highest 
tested concentration of DER (1000 µM) enhanced the cytotoxic activities of DOX 
significantly. Previous studies have shown that DOX toxicity can be mediated by 
the redox-shift dependent pathway as well as by topoisomerase II inhibition; the 
latter leads to DNA cleavage, caspase-3 activation and eventually apoptosis (Mi-
zutani et al., 2005). In our previous study, we have shown that DER induced 
apoptosis at 250 μM and higher concentrations in CMT-U27 cells (Üstün Alkan 
et al., 2012). Thus, it appears that DER-induced apoptosis may have contributed 
 IN VITRO EFFECTS OF DOXORUBICIN AND DERACOXIB ON OXIDATIVE STRESS 383 
Acta Veterinaria Hungarica 62, 2014 
to cell death. We suggested that DER-induced apoptosis of CMT-U27 cells was 
accompanied by alterations in antioxidant enzyme activities. 
Although NSAIDs are long-established and commonly used medications, 
their use as combination partners of conventional chemotherapeutic agents is 
very new and many things remain to be clarified. Considering that chemothera-
peutic agents increase oxidative stress and lower antioxidant capacity, NSAIDs 
may greatly improve therapeutic strategies. In the present study, we showed that 
DER attenuated DOX-induced oxidative damage by modulating oxidant status in 
CMT-U27 cells. We suggest that the combination of DOX and DER can be 
beneficial in the treatment of cancer cells by increasing cellular responses to oxi-
dative stress. Although an antioxidant property of DER has only been observed 
at high concentrations (500 and 1000 µM), these doses can be toxic in dogs. 
Also, the clinical benefit of using a DOX and DER combination in canine mam-
mary cancer patients is not known; therefore, in vivo clinical studies need to be 
conducted and evaluated to determine whether the combination of DOX and 
DER can be used safely in animals. 
In conclusion, the use of a COX inhibitor in combination with a chemo-
therapeutic agent may provide a basis for new concepts of cancer treatment with 
the help of systematic modulations of the antioxidant defence systems in mam-
mary cancer of animals. 
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